Charles River Laboratories ROE 2010-2024 | CRL
Current and historical return on equity (ROE) values for Charles River Laboratories (CRL) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Charles River Laboratories ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2024-12-31 |
$0.01B |
$3.47B |
0.30% |
| 2024-09-30 |
$0.42B |
$3.79B |
11.46% |
| 2024-06-30 |
$0.44B |
$3.73B |
12.35% |
| 2024-03-31 |
$0.44B |
$3.65B |
12.85% |
| 2023-12-31 |
$0.47B |
$3.60B |
14.27% |
| 2023-09-30 |
$0.47B |
$3.31B |
14.97% |
| 2023-06-30 |
$0.48B |
$3.26B |
16.12% |
| 2023-03-31 |
$0.50B |
$3.11B |
17.40% |
| 2022-12-31 |
$0.49B |
$2.98B |
17.83% |
| 2022-09-30 |
$0.44B |
$2.63B |
16.70% |
| 2022-06-30 |
$0.44B |
$2.65B |
17.31% |
| 2022-03-31 |
$0.42B |
$2.62B |
17.04% |
| 2021-12-31 |
$0.39B |
$2.54B |
16.49% |
| 2021-09-30 |
$0.40B |
$2.43B |
17.48% |
| 2021-06-30 |
$0.40B |
$2.32B |
18.57% |
| 2021-03-31 |
$0.38B |
$2.19B |
18.83% |
| 2020-12-31 |
$0.36B |
$2.12B |
19.59% |
| 2020-09-30 |
$0.30B |
$1.90B |
17.32% |
| 2020-06-30 |
$0.27B |
$1.76B |
16.46% |
| 2020-03-31 |
$0.25B |
$1.66B |
15.78% |
| 2019-12-31 |
$0.25B |
$1.64B |
16.71% |
| 2019-09-30 |
$0.23B |
$1.54B |
16.24% |
| 2019-06-30 |
$0.22B |
$1.46B |
16.11% |
| 2019-03-31 |
$0.23B |
$1.40B |
17.74% |
| 2018-12-31 |
$0.23B |
$1.32B |
18.51% |
| 2018-09-30 |
$0.14B |
$1.26B |
11.83% |
| 2018-06-30 |
$0.13B |
$1.19B |
11.73% |
| 2018-03-31 |
$0.13B |
$1.14B |
12.34% |
| 2017-12-31 |
$0.12B |
$1.05B |
12.56% |
| 2017-09-30 |
$0.20B |
$1.03B |
21.35% |
| 2017-06-30 |
$0.18B |
$0.97B |
20.69% |
| 2017-03-31 |
$0.17B |
$0.88B |
19.26% |
| 2016-12-31 |
$0.16B |
$0.84B |
18.61% |
| 2016-09-30 |
$0.14B |
$0.87B |
17.58% |
| 2016-06-30 |
$0.14B |
$0.84B |
18.39% |
| 2016-03-31 |
$0.16B |
$0.78B |
21.11% |
| 2015-12-31 |
$0.15B |
$0.74B |
21.27% |
| 2015-09-30 |
$0.15B |
$0.71B |
21.02% |
| 2015-06-30 |
$0.14B |
$0.71B |
20.56% |
| 2015-03-31 |
$0.13B |
$0.67B |
18.72% |
| 2014-12-31 |
$0.13B |
$0.68B |
18.50% |
| 2014-09-30 |
$0.12B |
$0.67B |
17.53% |
| 2014-06-30 |
$0.12B |
$0.68B |
17.48% |
| 2014-03-31 |
$0.11B |
$0.70B |
16.43% |
| 2013-12-31 |
$0.10B |
$0.64B |
15.94% |
| 2013-09-30 |
$0.10B |
$0.66B |
16.04% |
| 2013-06-30 |
$0.09B |
$0.65B |
14.97% |
| 2013-03-31 |
$0.10B |
$0.63B |
16.01% |
| 2012-12-31 |
$0.10B |
$0.60B |
16.53% |
| 2012-09-30 |
$0.11B |
$0.60B |
18.69% |
| 2012-06-30 |
$0.10B |
$0.57B |
18.65% |
| 2012-03-31 |
$0.10B |
$0.56B |
18.79% |
| 2011-12-31 |
$0.11B |
$0.53B |
19.61% |
| 2011-09-30 |
$-0.26B |
$0.54B |
-43.94% |
| 2011-06-30 |
$-0.31B |
$0.59B |
-42.47% |
| 2011-03-31 |
$-0.32B |
$0.56B |
-35.17% |
| 2010-12-31 |
$-0.34B |
$0.69B |
-30.01% |
| 2010-09-30 |
$0.02B |
$1.04B |
1.85% |
| 2010-06-30 |
$0.09B |
$1.39B |
6.25% |
| 2010-03-31 |
$0.11B |
$1.38B |
7.87% |
| 2009-12-31 |
$0.11B |
$1.37B |
8.73% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical Services |
$7.027B |
$4.050B |
|
Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support.
|
